Testosterone-Driven Growth-Hormone (GH) Secretion in Aging Men - Full Text View

Sponsor:	Mayo Clinic
Collaborator:	GlaxoSmithKline
Information provided by:	Mayo Clinic
ClinicalTrials.gov Identifier:	NCT00309855

Purpose

This study is being done to understand how testosterone, the major male sex hormone, controls the pituitary gland's secretion of growth hormone (GH). GH is an important metabolic hormone, which controls sugar; fat and protein use in the body and maintains muscle strength and bone calcium content. Both testosterone and GH decline in older men. The age-related fall in these hormones probably contributes to relative frailty, reduced quality of life, bone loss, muscle wasting and impaired sexual function.

Condition	Intervention
Aging	Drug: anastrazole or dutasteride

Study Type:	Interventional
Study Design:	Randomized, Double-Blind, Placebo Control, Parallel Assignment
Official Title:	Mechanisms of Testosterone-Driven Growth-Hormone (GH) Secretion in Aging Men: Modulation of GHRH, GHRP and Somatostatin Action by Estrogenic Versus Androgenic Steroids

Resource links provided by NLM:

Drug Information available for: Testosterone Propionate Methyltestosterone Testosterone Anastrozole Dutasteride Oxymesterone Testosterone enanthate Testosterone undecanoate

U.S. FDA Resources

Further study details as provided by Mayo Clinic:

Primary Outcome Measures:

How testosterone, controls the pituitary gland's secretion of growth hormone (GH).

Estimated Enrollment:	80
Study Start Date:	December 2005

Detailed Description:

Repletion of testosterone in older men drives pulsatile GH secretion via conjoint facilitation of feedforward by the primary secretagogues GHRH and GHRP and repression of feedback by the dominant inhibitor, somatostatin; and, in corollary, testosterone acts via aromatization to estradiol and/or reduction to 5 alpha-dihydrotestosterone

Eligibility

Ages Eligible for Study:	50 Years to 80 Years
Genders Eligible for Study:	Male
Accepts Healthy Volunteers:	Yes

Criteria

Inclusion Criteria:

healthy men between the ages of 50 and 80;
normal weight (within 30% of ideal body weight defined by New York Metropolitan Life tables); and
normal hematocrit (greater than 38%);
community dwelling; and
voluntarily consenting

Exclusion Criteria:

recent use of psychotropic or neuroactive drugs (within five biological half-live);
obesity (outside weight range above);
anemia (hematocrit < 38%);
drug or alcohol abuse, psychosis, depression, mania or severe anxiety;
acute or chronic organ-system disease;
endocrinopathy, other than primary thyroidal failure receiving replacement;
nightshift work or recent transmeridian travel (exceeding 3 time zones within 7 days of admission);
acute weight change (loss or gain of > 2 kg in 6 weeks);
allergy to administered compounds; and
unwillingness to provide written informed consent.

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00309855

Contacts

Contact: Johannes D. Veldhuis, M.D.

(507) 284-2511

Locations

United States, Minnesota
Mayo Clinic	Recruiting
Rochester, Minnesota, United States, 55905
Contact: Kristi L. Mielke 507-255-1294 mielke.kristi@mayo.edu

Sponsors and Collaborators

Mayo Clinic

GlaxoSmithKline

Investigators

Principal Investigator:

Johannes D. Veldhuis, M.D.

Mayo Clinic

More Information

No publications provided

Study ID Numbers:	319-03
Study First Received:	March 31, 2006
Last Updated:	March 31, 2006
ClinicalTrials.gov Identifier:	NCT00309855 History of Changes
Health Authority:	United States: Food and Drug Administration

Additional relevant MeSH terms:

Anastrozole
Molecular Mechanisms of Pharmacological Action
Antineoplastic Agents, Hormonal
Antineoplastic Agents
Physiological Effects of Drugs
Hormones, Hormone Substitutes, and Hormone Antagonists
Enzyme Inhibitors

Hormones
Pharmacologic Actions
Dutasteride
Testosterone
Therapeutic Uses
Aromatase Inhibitors
Androgens

ClinicalTrials.gov processed this record on November 20, 2009